HTG Molecular Diagnostics releases its HTG EdgeSeq Precision Immuno-Oncology Panel

HTG Molecular Diagnostics, Inc., a provider of instruments, reagents, and services for molecular profiling applications, release its HTG EdgeSeq Precision Immuno-Oncology Panel.

“Our Panel has been designed to simplify complex tumour biology and accelerate the development of clinical biomarkers. As Immuno-Oncology matures as a field, it is critical that translational tools evolve with the science to address immunotherapy acquired resistance or lack of response seen in broader cancer patient populations,” says Mark Stern, vice president of Immuno-Oncology at HTG.  “We have designed this panel to facilitate the molecular subtyping of tumours, allowing for the potential stratification of cancer into biological sub-groups, which might be sensitive to newly developed combination treatments. The new panel builds on HTG’s existing portfolio of assays, which leverage next-generation sequencing (NGS) to advance precision oncology.”

John Lubniewski, president and chief operating officer of HTG, says, “This comprehensive panel, with its multiple potential applications, supports our vision of helping researchers to advance their work and directly apply that knowledge to molecular testing. By using the HTG EdgeSeq Precision Immuno-Oncology Panel, researchers can go from raw sample to sequencing-ready libraries in as little as 36-hours, with less than four hours of hands-on time. We are also developing analytic modules to provide researchers with the answers they need when they need them. Our goal is to provide labs with a complete solution to empower precision medicine at the local level.”

The HTG EdgeSeq Precision Immuno-Oncology Panel includes applications such as the immunophenotyping of tumour infiltrating lymphocytes (TILs); monitoring of immunotherapy response biomarkers; and the elucidation of immune-escape mechanisms known to drive disease progression. Using only a single 5 µm formalin-fixed, paraffin-embedded (FFPE) tissue section, the panel can profile over one thousand genes, without the RNA extraction and complex workflow associated with standard RNA-seq methods. Together with the HTG EdgeSeq system, users will have the ability to profile using a wide variety of sample types allowing them to accelerate discovery, support translational applications, and determine potential biomarkers for the development of companion diagnostics.

Be the first to comment

Leave a Reply

Your email address will not be published.


*